Tianjin Institute of Pharmaceutical Research Co., Ltd.

Changying Liu

Lida Tang

Weiren Xu

Wei Liu

Guilong Zhao

Yuqiang Liu

Yuquan Li

Yafei Xie

Haizhi Zhang

Jingwei Wu

Huihui Chen

Meixiang Zou

Yuli Wang

Xuyuan Liu

Qian Shang

Chuan Li

Zhixing Zhou

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

Crystal form of urate transporter 1 inhibitor and preparation method and use thereof

Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization. 

Method for preparing urate transporter 1 inhibitor

The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, 

Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof

Growing community of inventors

Tianjin, China

Changying Liu